Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Indexes
  3. Spain
  4. Bolsas y Mercados Espanoles
  5. IBEX 35
  6. News
  7. Summary
    IB   ES0SI0000005


SummaryMost relevantAll NewsOther languagesNews of the index componentsMarketScreener Strategies

PRESS RELEASE: MC2 Therapeutics: Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora(R) Cream for treatment of Plaque Psoriasis

02/17/2021 | 03:03am EDT
DGAP-News: MC2 Therapeutics / Key word(s): Agreement/Market launch 
MC2 Therapeutics: Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for 
European Rights to Wynzora(R) Cream for treatment of Plaque Psoriasis 
2021-02-17 / 09:00 
The issuer is solely responsible for the content of this announcement. 
Almirall and MC2 Therapeutics Enter a License, Collaboration and Commercialization Agreement for European Rights to 
Wynzora(R) Cream for Treatment of Plaque Psoriasis 
In this collaboration Almirall will commercialize Wynzora(R) Cream for treatment of plaque psoriasis in Europe and MC2 
Therapeutics will be responsible for manufacturing and supply. 
- MC2 Therapeutics and Almirall partner to make Wynzora(R) Cream a leading topical product for Plaque Psoriasis in 
- In a large European based Phase 3 clinical trial (n=490), Wynzora(R) Cream has demonstrated substantial efficacy with 
a PGA treatment success of 51% and beneficial treatment convenience (1) 
- Marketing Authorization Application (MAA) in Europe of Wynzora(R) Cream has been filed and approval is expected this 
BARCELONA, Spain and COPENHAGEN, Denmark, February 17, 2021 -- Almirall S.A. (BME: ALM), a global biopharmaceutical 
company and MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard within topical 
therapies for autoimmune and chronic inflammatory conditions, announced today an agreement under which MC2 Therapeutics 
has granted Almirall exclusive European rights to commercialize Wynzora(R) Cream for treatment of plaque psoriasis. In 
exchange, MC2 Therapeutics is eligible to receive upfront to launch payments of EUR 15 million in addition to 
significant sales milestone payments and double-digit royalties on the European sales of Wynzora(R) Cream. Almirall and 
MC2 Therapeutics partner to make Wynzora(R) Cream a leading topical product for treatment of plaque psoriasis in Europe 
- a market, which currently is more than 25 million units in sales volume annually (2). The market represents a 
significant opportunity for Wynzora(R) Cream as the calcipotriene and betamethasone dipropionate segment accounts for 
approximately 35% of share of volume and annual sales of more than USD300 million (2). 
Wynzora(R) Cream (50 µg/g calcipotriol and 0.5 mg/g betamethasone as dipropionate) received US FDA approval on 20th 
July 2020. Wynzora(R) Cream is currently under review in Europe supported by two Phase 3 trials (1), including an EU 
head-to-head trial against active comparator Dovobet/Daivobet(R) Gel. The Physician Global Assessment (PGA) treatment 
success defined as a minimum two-point decrease in the PGA score to clear or almost clear disease at Week 8 was 51% for 
Wynzora(R) Cream vs. 6% for vehicle (p<0.0001). The treatment satisfaction score using the Psoriasis Treatment 
Convenience Scale (PTCS) was superior compared to Dovobet/Daivobet(R) Gel. Using MC2 Therapeutics' PAD(TM) Technology, 
Wynzora(R) Cream was uniquely designed to provide patients a new treatment option in their daily routines by combining 
the three essentials of a topical therapy in one single product namely high efficacy, a favorable safety profile and 
convenience of use. 
Mike Mcclellan, Chief Financial Officer (CFO) and interim Chief Executive Officer (CEO) said: "We are thrilled with 
this agreement with MC2 Therapeutics. Wynzora(R) Cream has demonstrated significant improvements in the skin clearance 
of psoriasis patients. It is the perfect addition to our growing psoriasis portfolio, which includes multiple treatment 
options, covering the whole spectrum of the disease. We are delighted that soon we will be able to offer this novel 
topical treatment to European dermatologists and their patients." 
Jesper J. Lange, CEO of MC2 Therapeutics, commented: "We are excited to partner with Almirall, an established company 
with deep expertise in dermatology and psoriasis and with the focus to improve patients' needs. Bringing together 
Almirall's excellence in commercial operations and MC2 Therapeutics' commitment to ensure a global roll-out of Wynzora 
(R) Cream we will, upon approval, ensure a strong launch of Wynzora(R) Cream for the benefit of the many patients 
living with plaque psoriasis and for the healthcare practitioners who provide care. We believe that the unique 
combination of compelling clinical efficacy, a favorable safety profile and treatment convenience are key components to 
treatment adherence and overall better patient satisfaction in topical treatment of plaque psoriasis in a real-world 
About Plaque Psoriasis 
Psoriasis is a common, non-contagious, chronic skin disease, with no clear cause or cure. The negative impact of plaque 
psoriasis on people's lives can be immense as it affects the appearance of the skin with red, scaly plaques. Psoriasis 
affects people of all ages, and in all countries. The reported prevalence of psoriasis in Europe varies from 0.6% to 
6.5% with an average of approximately 3% of the population (3,4), making psoriasis a serious global problem with more 
than 100 million individuals affected worldwide (5). The flares of psoriasis can be unpredictable and significant 
comorbidities are common, including arthritis, cardiovascular diseases, metabolic syndrome, inflammatory bowel disease 
and depression (4). 
About Wynzora(R) Cream 
Wynzora(R) Cream (50 µg/g calcipotriol and 0.5 mg/g betamethasone as dipropionate) is under review in Europe as a 
topical treatment of plaque psoriasis in adults. Wynzora^(R) Cream is based on PAD(TM) Technology, enabling an aqueous 
cream formulation of both calcipotriol and betamethasone as dipropionate and optimal delivery of active ingredients 
into the target tissue. Wynzora^(R) Cream was approved in the US by the FDA on 20^th July 2020. 
About Almirall 
Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare 
professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of 
our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest 
in differentiated and groundbreaking medical dermatology products to bring our innovative solutions to patients in 
The company, founded in 1943 and headquartered in Barcelona, is public traded on the Spanish Stock Exchange and is a 
member of the IBEX 35 (BME: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of 
patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 
subsidiaries, with about 1,800 employees. Total revenues in 2019 were 908.4 million euros. 
For additional information on Almirall, please visit www.almirall.com 
About MC2 Therapeutics 
MC2 Therapeutics is a privately held commercial stage pharmaceutical company committed to build leadership in topicals 
for autoimmune and chronic inflammatory conditions. Our focus is to develop and advance best in class or first in class 
therapies by understanding the pathophysiology and researching novel compounds. Our ultimate goal is to minimize the 
burden of disease for patients by addressing unmet needs. 
Using PAD(TM) Technology we are introducing a new standard of topical treatment experience for the benefit of patients, 
physicians, payers and societies. Our innovative pipeline is comprised of drug candidates within uremic pruritus, 
lichen sclerosis, Sjogren's syndrome dry eye, ocular rosacea and atopic dermatitis. 
For additional information on MC2 Therapeutics Group, please visit www.mc2therapeutics.com 
Forward-Looking Statements 
The above information contains forward-looking statements that provide our expectations or forecasts of future events. 
This can be such as the impact of the global COVID-19 pandemic on our business, new product introductions, clinical 
development activities and anticipated results, product approvals, financial performance. Terms used may be "aspire", 
"believes," "potential," "proposed," "continue," "designed," "anticipates," "expects," "plans," "intends," "may," 
"could," "might," "will," "should" or other words or expressions referencing future events, conditions or circumstances 
that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking 
statements are subject to risks and uncertainties. This may cause actual results to differ materially from expectations 
and it may cause any or all our forward-looking statements here or in other publications to be wrong. Factors that may 
affect future results include the impact of the global COVID-19 pandemic, interest rate and currency exchange rate 
fluctuations, delay or failure of clinical trials and other development activities, production problems, unexpected 
contract breaches or terminations. 
Corporate Communications 
Mar Ramírez 
(+34) 659 614 173 
Investors Relations 
Pablo Divasson del Fraile 
(+34) 93 291 30 87 
MC2 Therapeutics 
Corporate Communications, Media and Investors 
Susanne Andersen Fitch 
(+45) 3131 5119 
1. Clinical trial IDs: NCT03802344 and NCT03308799 on Clinicaltrials.gov 
3. Chandran, V., and S.P. Raychaudhuri. 2010. 'Geoepidemiology and environmental factors of psoriasis and psoriatic 
arthritis', J. Autoimmune, 34: J314-J21 
4. Schafer, T. 2006. 'Epidemiology of psoriasis. Review and the German perspective', Dermatology, 212: 327-37 
5. WHO Global report on Psoriasis 2016 
2021-02-17 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 

(MORE TO FOLLOW) Dow Jones Newswires

February 17, 2021 03:02 ET (08:02 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
ALMIRALL, S.A. 0.99% 14.33 Delayed Quote.31.23%
IBEX 35 0.31% 8760.9 Delayed Quote.8.51%
All news about IBEX 35
09/17STOXX EUROPE 600 : European Bourses Edging Lower Midday After Higher Inflation R..
09/16IBEX : Citigroup Adjusts Price Target for IBEX to $23 From $29, Maintains Buy Ra..
09/16European Bourses Rally Midday on ECB Outlooks, Energy Shares
09/15STOXX EUROPE 600 : European Bourses Slip Midday on Slowing Global Growth Outlook
09/15IBEX : Piper Sandler Cuts Price Target on IBEX to $22 From $25, Maintains Overwe..
09/14IBEX : Fiscal Q4 Adjusted Earnings, Revenue Rise; Shares Fall After-Hours
09/14IBEX : Entering Honduras With Delivery Center
09/14STOXX EUROPE 600 : European Bourses Steady Midday as Financial Issues Slip, Oil ..
09/13STOXX EUROPE 600 : European Bourse Bourses Track Higher Midday Led by Bank, Oil,..
09/10STOXX EUROPE 600 : European Bourses Higher Midday After Biden-Xi Talk, ECB Polic..
More news
News of the index components IBEX 35
10:21aINTERNATIONAL CONSOLIDATED AIRLINES : BA owner IAG says group will not tap inve..
09/17Analysis-Europe's power firms locked out of record price bonanza
09/17European ADRs Down Nearly 2% Friday as Mining, Steel Shares Drop
09/17IBERDROLA S A : Connecting the Iberian Peninsula with the other countries of the..
09/17CELLNEX TELECOM S A : CK Hutchison Attempt To Dissuade UK Watchdog From Asset Sa..
09/17SIEMENS GAMESA : UBS sticks Neutral
09/17GRIFOLS S A : Form 6-K)
More news
Chart IBEX 35
Duration : Period :
IBEX 35 Technical Analysis Chart | IB | ES0SI0000005 | MarketScreener
Technical analysis trends IBEX 35
Short TermMid-TermLong Term
Heatmap :